EXACT Sciences (EXAS) Stock Price Down 0%

EXACT Sciences Co. (NASDAQ:EXAS) traded down 0% during trading on Friday . The company traded as low as $37.36 and last traded at $37.84. 2,043,208 shares changed hands during trading, a decline of 31% from the average session volume of 2,959,455 shares. The stock had previously closed at $37.84.

A number of equities research analysts have recently commented on the company. Zacks Investment Research upgraded EXACT Sciences from a “hold” rating to a “buy” rating and set a $62.00 target price on the stock in a research report on Tuesday, January 16th. William Blair reaffirmed a “buy” rating on shares of EXACT Sciences in a research note on Wednesday, January 10th. BidaskClub raised shares of EXACT Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, December 21st. Robert W. Baird raised shares of EXACT Sciences from a “neutral” rating to an “outperform” rating and raised their price target for the company from $42.56 to $56.00 in a research note on Tuesday, February 27th. Finally, Goldman Sachs began coverage on shares of EXACT Sciences in a research note on Monday, January 29th. They issued a “neutral” rating and a $51.00 price target on the stock. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. EXACT Sciences currently has an average rating of “Buy” and an average price target of $52.84.

How to Become a New Pot Stock Millionaire

The company has a current ratio of 7.15, a quick ratio of 6.77 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $4,576.45, a price-to-earnings ratio of -38.22 and a beta of 0.87.

EXACT Sciences (NASDAQ:EXAS) last released its earnings results on Thursday, February 22nd. The medical research company reported ($0.18) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.09. EXACT Sciences had a negative net margin of 43.01% and a negative return on equity of 24.13%. The business had revenue of $87.41 million for the quarter, compared to analyst estimates of $87.42 million. During the same period last year, the company posted ($0.34) EPS. The business’s revenue was up 148.0% on a year-over-year basis. analysts anticipate that EXACT Sciences Co. will post -0.92 EPS for the current year.

In other EXACT Sciences news, insider Kevin T. Conroy sold 125,402 shares of the firm’s stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $52.79, for a total value of $6,619,971.58. Following the transaction, the insider now directly owns 955,454 shares of the company’s stock, valued at approximately $50,438,416.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP D Scott Coward sold 4,420 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $42.34, for a total transaction of $187,142.80. The disclosure for this sale can be found here. Insiders sold a total of 449,995 shares of company stock worth $21,876,323 over the last three months. Corporate insiders own 4.00% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in EXAS. New York State Common Retirement Fund raised its position in shares of EXACT Sciences by 35.1% during the 3rd quarter. New York State Common Retirement Fund now owns 211,819 shares of the medical research company’s stock valued at $9,981,000 after buying an additional 55,078 shares during the period. Bank of New York Mellon Corp raised its position in shares of EXACT Sciences by 7.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 661,937 shares of the medical research company’s stock valued at $31,189,000 after buying an additional 45,792 shares during the period. SG Americas Securities LLC purchased a new stake in shares of EXACT Sciences during the 3rd quarter valued at approximately $183,000. Great West Life Assurance Co. Can raised its position in shares of EXACT Sciences by 23.6% during the 3rd quarter. Great West Life Assurance Co. Can now owns 13,304 shares of the medical research company’s stock valued at $616,000 after buying an additional 2,543 shares during the period. Finally, Legal & General Group Plc raised its position in shares of EXACT Sciences by 19.1% during the 3rd quarter. Legal & General Group Plc now owns 50,437 shares of the medical research company’s stock valued at $2,366,000 after buying an additional 8,101 shares during the period. 82.02% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “EXACT Sciences (EXAS) Stock Price Down 0%” was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3340854/exact-sciences-exas-stock-price-down-0.html.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

$1.35 EPS Expected for Darden Restaurants  This Quarter
$1.35 EPS Expected for Darden Restaurants This Quarter
BumbaCoin Reaches Market Cap of $124,516.00
BumbaCoin Reaches Market Cap of $124,516.00
AICHAIN  Reaches 1-Day Volume of $34,278.00
AICHAIN Reaches 1-Day Volume of $34,278.00
JobsCoin  Trading Down 37.7% Over Last Week
JobsCoin Trading Down 37.7% Over Last Week
$2.56 Billion in Sales Expected for Discover Financial Services  This Quarter
$2.56 Billion in Sales Expected for Discover Financial Services This Quarter
Zacks: Analysts Anticipate Dover Co.  to Post $1.15 Earnings Per Share
Zacks: Analysts Anticipate Dover Co. to Post $1.15 Earnings Per Share


Leave a Reply

© 2006-2018 Ticker Report. Google+.